Biomarkers of inflammation, coagulation, lipids and vitamin D have been associated with cardiovascular and mortality risk in HIV-infected individuals. Scarce data exist on changes in these markers from pre-to post-HIV seroconversion.
Methods
The study participants were drawn from the Health in Men Study, which recruited HIV-negative homosexual men. Participants with incident HIV infection (n=26) were compared with HIV-negative controls (n=52) matched on age at enrolment, date of visit and reported intravenous drug use. Levels of metabolic (lipids and vitamin D), inflammatory (C-reactive protein and interleukin-6) and coagulation (D-dimer and fibrinogen) biomarkers were measured at pre- and post-HIV seroconversion visits and corresponding visits for controls. Random-effect models were used to compare changes in markers between cases and controls.
Results
The median gap between pre- and post-seroconversion or matched first and second visits in controls was 12 months. HIV seroconversion was associated with decline in high density lipoprotein (HDL-C; difference in mean change between cases and controls -0.14 mmol/l; 95% CI -0.22, -0.01; P=0.035). There were no significant differences in changes in other lipids, markers of inflammation, coagulation or vitamin D.
Conclusions
Decline in HDL-C seems to be the main proatherogenic change within 1–1.5 years after HIV seroconversion. HIV seroconversion was not associated with profound changes in other lipids, or markers of inflammation, coagulation and vitamin D. Longitudinal assessment of these markers in comparable population needs further assessment.
References
1.
BakerJ.V., LundgrenJ.D.Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J2011; 32: 945–951.
2.
TriantV.A.HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis2012; 205: S355–S361.
3.
NeuhausJ., JacobsD.R., BakerJ.V.Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis2010; 201: 1788–1795.
4.
ArmahK.A., McGinnisK., BakerJ.HIV status, burden of comorbid disease and biomarkers of inflammation, altered coagulation and monocyte activation. Clin Infect Dis2012; 55: 126–136.
5.
BakerJ., AyenewW., QuickH.High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis2010; 201: 285–292.
6.
KullerL.H., TracyR., BellosoW.Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med2008; 5: e203.
7.
AchhraA.C., AminJ., SabinC.Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. AIDS2012; 26: 1707–1717.
8.
ChoiA.I., LoJ.C., MulliganK.Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis2011; 52: 941–944.
9.
ViardJ-P, SouberbielleJ-C, KirkO.Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS2011; 25: 1305–1315.
10.
NeatonJ.D., NeuhausJ., EmeryS.Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin in HIV AIDS2010; 5: 480–490.
11.
DaoC.N., PatelP., OvertonE.T.Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis2011; 52: 396–405.
12.
RiddlerS.A., SmitE., ColeS.R.Impact of HIV infection and HAART on serum lipids in men. JAMA2003; 289: 2978–2982.
13.
ReddA.D., EatonK.P., KongX.C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation. J Acquir Immune Defic Syndr2010; 54: 556–559.
14.
PrestageG., Van de VenP., MaoL.Contexts for last occasions of unprotected anal intercourse among HIV-negative gay men in Sydney: the health in men cohort. AIDS Care2005; 17: 23–32.
15.
JinF., PrestageG.P., ZablotskaI.High rates of sexually transmitted infections in HIV positive homosexual men: data from two community based cohorts. Sex Transm Infect2007; 83: 397–399.
16.
Friis-MøllerN., ThiebautR., ReissP.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil2010; 17: 491–501.
17.
EastburnA., ScherzerR., ZolopaA.R.Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS ONE2011; 6: e26320.
